×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVS – novartis ag (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/16
03:05 pm
nvs
Novartis (NYSE:NVS) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Low
Report
Novartis (NYSE:NVS) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
1/15
05:52 pm
nvs
Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
Low
Report
Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
1/14
08:53 pm
nvs
JPM26: Vor Bio narrows focus to two-indication strategy [Yahoo! Finance]
Low
Report
JPM26: Vor Bio narrows focus to two-indication strategy [Yahoo! Finance]
1/13
07:31 pm
nvs
Novartis CEO Dr. Vasant Narasimhan sits down with Jim Cramer [CNBC]
Low
Report
Novartis CEO Dr. Vasant Narasimhan sits down with Jim Cramer [CNBC]
1/13
06:18 pm
nvs
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
Medium
Report
Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight [Yahoo! Finance]
1/13
10:31 am
nvs
Acute Myeloid Leukemia Market Analysis and Forecast, 2025-2035: Precision Medicine Leads Growth [Yahoo! Finance]
Low
Report
Acute Myeloid Leukemia Market Analysis and Forecast, 2025-2035: Precision Medicine Leads Growth [Yahoo! Finance]
1/12
09:52 am
nvs
SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs [Yahoo! Finance]
Low
Report
SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs [Yahoo! Finance]
1/12
08:55 am
nvs
SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease [Yahoo! Finance]
Low
Report
SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/25
06:01 am
nvs
Form 6-K NOVARTIS AG For: Nov 24
Low
Report
Form 6-K NOVARTIS AG For: Nov 24
11/20
06:05 am
nvs
Form 6-K NOVARTIS AG For: Nov 20
Low
Report
Form 6-K NOVARTIS AG For: Nov 20
11/5
04:33 pm
nvs
Form 6-K NOVARTIS AG For: Nov 05
Low
Report
Form 6-K NOVARTIS AG For: Nov 05
11/4
06:08 am
nvs
Form FWP NOVARTIS AG Filed by: NOVARTIS AG
Low
Report
Form FWP NOVARTIS AG Filed by: NOVARTIS AG
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/4
BRIEF-Novartis has stock to cover production, distribution for now, monitoring India API changes [Reuters]
4.8%
7/17 The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On [The Motley Fool] 4.5%
5/23 Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency 3.6%
8/11 5 Reasons Novartis Shareholders Aren't Shaken [The Motley Fool] 3.4%
8/7 Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS) 2.7%
4/4 Novartis AG (NYSE: NVS) had its "buy" rating re-affirmed by analysts at Goldman Sachs Group Inc. They now have a $116.00 price target on the stock. 2.7%
4/13 Novartis: Recent Selloff Has Presented A Buying Opportunity [Seeking Alpha] 2.4%
3/24 BRIEF-Novartis says Zolgensma helped SMA patients up to 5 years after dosing [Reuters] 2.2%
4/2 New York City hospital worker who caught coronavirus returns to treat patients [FOX News] 2.2%
3/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 1.9%
7/17 The Multibillion-Dollar Race for Gene Therapy Manufacturing Is On [The Motley Fool] 4.5%
5/23 Sosei Heptares Notes That a Valid Marketing Authorization Application For QVM149, a Potential New Inhaled Combination Therapy For Asthma, Has Been Filed With the European Medicines Agency 3.6%
8/11 5 Reasons Novartis Shareholders Aren't Shaken [The Motley Fool] 3.4%
8/7 Glancy Prongay & Murray LLP Announces Investigation on Behalf of Novartis AG Investors (NVS) 2.7%
4/4 Novartis AG (NYSE: NVS) had its "buy" rating re-affirmed by analysts at Goldman Sachs Group Inc. They now have a $116.00 price target on the stock. 2.7%
4/13 Novartis: Recent Selloff Has Presented A Buying Opportunity [Seeking Alpha] 2.4%
3/24 BRIEF-Novartis says Zolgensma helped SMA patients up to 5 years after dosing [Reuters] 2.2%
4/2 New York City hospital worker who caught coronavirus returns to treat patients [FOX News] 2.2%
3/10 INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm 1.9%
TOP News Decliners
2/24
BRIEF-Novartis Announces FDA And EMA Filing Acceptance Of Ofatumumab [Reuters]
-6.9%
4/28 Novartis sales, profits rise in first quarter on COVID-19 buying rush [Reuters (UK)] -3.2%
2/25 Novartis AG (NYSE: NVS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -3.0%
9/13 BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient [Reuters] -2.8%
4/6 Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works [Reuters] -2.7%
3/3 BRIEF-Novartis Receives Health Canada Approval For Mayzent [Reuters] -2.7%
3/20 UPDATE 2-Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.4%
7/11 BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520 [Reuters] -2.3%
3/9 ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS -2.2%
3/20 Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.2%
4/28 Novartis sales, profits rise in first quarter on COVID-19 buying rush [Reuters (UK)] -3.2%
2/25 Novartis AG (NYSE: NVS) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating. -3.0%
9/13 BRIEF-Novartis Says Neuronal And Glial Filaments Have Potential To Support Management Of MS Patient [Reuters] -2.8%
4/6 Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works [Reuters] -2.7%
3/3 BRIEF-Novartis Receives Health Canada Approval For Mayzent [Reuters] -2.7%
3/20 UPDATE 2-Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.4%
7/11 BRIEF-Novartis, Amgen And Banner Alzheimer's Institute Discontinue Clinical Program With Bace Inhibitor CNP520 [Reuters] -2.3%
3/9 ROSEN, A LEADING LAW FIRM, Continues to Investigate Securities Claims Against Novartis AG – NVS -2.2%
3/20 Novartis to donate malaria drug in fight against coronavirus [Reuters] -2.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: